Skip to main content


  • Erratum
  • Open Access

Erratum to: A retrospective study to identify risk factors for somnolence and dizziness in patients treated with pregabalin

  • 1, 2Email author,
  • 1, 2,
  • 2,
  • 3,
  • 3,
  • 1, 2 and
  • 1
Journal of Pharmaceutical Health Care and Sciences20162:5

  • Received: 11 February 2016
  • Accepted: 11 February 2016
  • Published:

The original article was published in Journal of Pharmaceutical Health Care and Sciences 2015 1:22


Unfortunately, after publication of the original version of this article [1], it was noticed that some author corrections were not included in the final article.
  • Within the “Methods” section, the Cockcroft-Gault equation should read as follows:
    • $$ \mathrm{CLcr}\ \left(\mathrm{mL}/ \min \right) = \left(\mathbf{140} - \mathrm{age}\right) \times \mathrm{weight}\ \left(\mathrm{kg}\right)\ /\ \left\{\mathbf{72} \times \mathrm{serum}\ \mathrm{creatinine}\ \left(\mathrm{mg}/\mathrm{dL}\right)\right\} \times \mathbf{0.85}\ \left(\mathrm{if}\ \mathrm{female}\right) $$
  • In addition Table 1 contained some formatting errors. The correct version of Table 1 is included below.
    Table 1

    Patient characteristics (n = 204)


     Median, year


     Range, year



     Male, n(%)

    123 (60.3)

     Female , n(%)

    81 (39.7)

    Median CLcra, mL/min


    NPb origin

     Cancer related NP, n(%)

    55 (27.0)

     Chemotherapy related NP, n(%)

    24 (11.7)

     Non-cancer related NP, n(%)

    125 (61.3)

    Regular strong opioid

     yes, n(%)

    36 (17.6)

      -fentanyl, n


      -oxycodone, n


      -morphine, n


      Median dosec (range), mg/day

    60 (15–300)

     no, n(%)

    168 (82.4)

    Initial dose of pregabalin

     150 mg/day, n(%)

    124 (60.8)

     75 mg/day, n(%)

    73 (35.8)

     50 mg/day, n(%)

    3 (1.5)

     25 mg/day, n(%)

    4 (1.9)

    aCLcr: creatinine clearance using the Cockcroft-Gault equation

    bNP: neuropathic pain

    cconverted to oral morphine



Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

Department of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya Aichi, 466-8560, Japan
Division of Clinical Sciences and Neuropsychopharmacology, Meijo University Faculty of Pharmacy, Nagoya, Japan
Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan


  1. Kato H, Miyazaki M, Takeuchi M, Tsukuura H, Sugishita M, Noda Y, et al. A retrospective study to identify risk factors for somnolence and dizziness in patients treated with pregabalin. J Pharm Health Care Sci. 2015;1:22. doi:10.1186/s40780-015-0022-7.PubMed CentralView ArticlePubMedGoogle Scholar


© Kato et al. 2016